Maryam Dashtiahangar, Leila Rahbarnia, Safar Farajnia*, Arash Salmaninejad, Arezoo Gowhari Shabgah and Samaneh Ghasemali Pages 1 - 10 ( 10 )
The development of recombinant immunotoxins (RITs) as a novel therapeutic strategy has made a revolution in the treatment of cancer. RITs are resulting from the fusion of antibodies to toxin proteins for targeting and eliminating cancerous cells by inhibiting protein synthesis. Despite indisputable outcomes of RITs regarding inhibiting multiple cancer types, high immunogenicity has been known as the main obstacle in the clinical use of RITs. Various strategies have been proposed to overcome these limitations, including immunosuppressive therapy, humanization of the antibody fragment moiety, generation of immunotoxins originated from endogenous human cytotoxic enzymes, and modification of the toxin moiety to escape the immune system. This paper devoted to reviewing recent advances in the design of immunotoxins with lower immunogenicity.
Recombinant immunotoxin, toxins, immunogenicity, immunosuppressive therapy, anti-drug antibodies
Department of Biology, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad, Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Halal Research Center of IRI, FDA, Tehran, Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz